Clinical Trials Logo

Safety clinical trials

View clinical trials related to Safety.

Filter by:

NCT ID: NCT01166698 Completed - Healthy Volunteers Clinical Trials

Single Centre, Double-blind, Single and Multiple Ascending Inhaled Doses of AZD9819 in Healthy Subjects

Start date: August 2010
Phase: Phase 1
Study type: Interventional

The purpose of the study is to assess safety and tolerability of AZD9819 following inhaled administration of single and multiple increasing doses, and to estimate the maximum dose that is tolerated in healthy people.

NCT ID: NCT01091532 Completed - Safety Clinical Trials

A Study In Healthy People Of Multiple Doses Of UK-396,082 Given By Mouth, To Investigate The Safety, Toleration And Time Course Of Blood Concentration Of UK-396,082 And Its Effects.

Start date: March 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study in healthy people is to investigate the safety, toleration and time course of UK-396,082 concentration in the blood and any changes in relevant markers of drug effects, following multiple doses given twice daily by mouth for 14 days.

NCT ID: NCT01086813 Withdrawn - Pharmacokinetics Clinical Trials

Phase I, Single Centre, Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD3043

AZD3043
Start date: March 2010
Phase: Phase 1
Study type: Interventional

Phase I, Single Centre, Open Label Study to Assess the Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of Intravenous AZD3043 after aSingle Ascending Bolus Dose Followed by a Single Infusion Dose in Elderly(=65 years) Healthy Volunteers

NCT ID: NCT01026038 Completed - Safety Clinical Trials

Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.

Start date: April 2010
Phase: Phase 3
Study type: Interventional

This is an open-label study (a study in which the doctors and participants know which drug or vaccine is being administered) in children who previously received a 4-dose series of a pneumococcal conjugate vaccine (PnC) during infancy in Study 6096A1-008-EU (NCT00366678). In this study, participants will receive an additional dose of 13-valent pneumococcal conjugate vaccine. The purpose of this study is to evaluate persistence, if any, of the antibody response by measuring any remaining pneumococcal antibodies since the previous study. This study will also evaluate the safety and immunogenicity of 13-valent pneumococcal conjugate vaccine when administered at least 24 months after the last dose of pneumococcal conjugate vaccine.

NCT ID: NCT00696865 Completed - Healthy Clinical Trials

AZD2624 Multiple Ascending Dose Study in Japan

JMAD
Start date: May 2008
Phase: Phase 1
Study type: Interventional

This multiple ascending dose study will evaluate safety and tolerability after repeated ascending doses of AZD2624

NCT ID: NCT00461565 Completed - Safety Clinical Trials

FDA Phase IV - Commitment - Retinal Function Study

Start date: February 2005
Phase: Phase 4
Study type: Interventional

Vardenafil (Levitra) and Sildenafil (Viagra) are drugs that are marketed for use in patients with erectile dysfunction. The purpose of this study is to find out if there are any changes in the eye after taking at least 15 doses of Vardenafil and after two doses of Sildenafil. This is a double-blind study, which means that neither you nor the study doctor will know which treatment you are receiving. If you qualify for the study, you will receive:- Vardenafil 20 mg twice per week (Monday and Thursday) for a maximum of 8 weeks. There will be two times when this occurs during the study.- Sildenafil 200 mg/day for two days. There will be two times when this occurs during the study. - Placebo (a pill that looks like vardenafil or sildenafil but has no active ingredient).

NCT ID: NCT00256386 Completed - Safety Clinical Trials

LabAlert: Enhancing Medication Safety Through Electronic Interventions to Improve Laboratory Monitoring

Start date: January 2004
Phase: N/A
Study type: Interventional

Errors and preventable adverse events associated with medication prescription and dispensing are common, and the difference between guideline recommendations and the actual frequency of laboratory monitoring is substantial. This study evaluates three interventions to improve laboratory monitoring at initiation of medication therapy: an electronic medical record reminder to the prescribing clinician (EMR), an automated voice message to the patient (AVM), and a pharmacy team outreach (Pharmacy) compared to usual care (UC).